- Report
- March 2025
- 175 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- March 2025
- 175 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- March 2025
- 175 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Drug Pipelines
- April 2024
- 180 Pages
Global
From €2863EUR$3,000USD£2,399GBP
- Report
- August 2022
- 115 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- November 2023
- 353 Pages
Global
From €9067EUR$9,500USD£7,597GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2625EUR$2,750USD£2,199GBP
- Report
- April 2023
- 120 Pages
Global
From €4533EUR$4,750USD£3,798GBP
Afinitor is a drug used to treat certain types of lung cancer. It is a type of targeted therapy, which works by blocking certain proteins that help cancer cells grow and divide. It is used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is no longer responding to other treatments. Afinitor is also used to treat certain types of kidney cancer. It is usually taken in combination with other drugs.
Afinitor is a relatively new drug, and is still in the early stages of development. It is not yet widely available, and is only approved for use in certain countries. However, it is gaining popularity as a treatment for lung cancer, and is being studied in clinical trials for other types of cancer.
The Afinitor market is highly competitive, with several companies developing and marketing the drug. These include Novartis, Pfizer, and AstraZeneca. Other companies are also researching and developing similar drugs, such as Merck and Bristol-Myers Squibb. Show Less Read more